Shingles Vaccine Safe & Effective in Autoimmune Disease – Except With Rituximab/Mycophenolate

For individuals living with autoimmune rheumatic diseases, the prospect of preventing shingles – a painful and potentially debilitating condition – just became clearer. Recent research indicates that the herpes zoster vaccine is generally safe for this population and effectively stimulates an immune response. Yet, the study, published in Medscape Medical News, also highlights that those currently undergoing treatment with certain immunosuppressant medications may experience a diminished immune response to the vaccine.

Understanding Shingles and Vaccination

Shingles, also known as herpes zoster, is a reactivation of the varicella-zoster virus, the same virus that causes chickenpox. After a chickenpox infection, the virus remains dormant in nerve cells. As people age, or if their immune system is weakened, the virus can reactivate, causing a painful rash, often with blisters, typically on one side of the body. Complications can include long-term nerve pain, known as postherpetic neuralgia, and, less commonly, vision loss or neurological problems.

Vaccination is the most effective way to prevent shingles. The currently recommended vaccine, Shingrix, is a recombinant subunit vaccine, meaning it doesn’t contain live virus and is considered safe for most people, even those with weakened immune systems. However, the effectiveness of the vaccine can vary depending on the degree of immune suppression.

The Phase 4 Study: Findings and Population

The phase 4 study examined the safety and immunogenicity (the ability to provoke an immune response) of the Shingrix vaccine in adults with autoimmune rheumatic diseases. These conditions, which include rheumatoid arthritis, lupus, and psoriasis, are characterized by chronic inflammation and often require immunosuppressive medications to manage symptoms. The study involved a diverse group of patients with various rheumatic diseases, providing a broader understanding of vaccine response across different conditions.

Researchers found that the vaccine was well-tolerated, with no new safety concerns identified. Importantly, the vaccine elicited a strong immune response in most participants. However, individuals receiving rituximab or mycophenolate mofetil – both immunosuppressant drugs commonly used to treat autoimmune diseases – demonstrated weaker immune responses compared to those not on these medications. The New England Journal of Medicine published related research on rituximab and mycophenolate mofetil in patients with pemphigus vulgaris, a rare autoimmune blistering skin disease, further illustrating the impact of these drugs on immune response.

Implications for Patients on Immunosuppressants

The findings suggest that while the Shingrix vaccine is still considered safe for individuals on rituximab or mycophenolate, the protection it offers may be reduced. This doesn’t necessarily mean the vaccine is ineffective, but it highlights the importance of discussing vaccination strategies with a healthcare provider. The timing of vaccination relative to medication infusions or doses may also be a factor, though further research is needed to determine the optimal approach.

It’s crucial to understand that the study assessed immune response, not necessarily clinical protection against shingles. A weaker immune response doesn’t automatically translate to a higher risk of developing shingles, but it does suggest that the vaccine might not provide the same level of protection as it would in someone with a fully functioning immune system.

Navigating Vaccination Guidelines for Immunocompromised Individuals

Vaccination recommendations for immunocompromised individuals are complex, and evolving. Healio recently reported on the varying vaccination guidelines for these patients, emphasizing the need for individualized assessment. The Centers for Disease Control and Prevention (CDC) provides general guidance on shingles vaccination, but specific recommendations should be made by a healthcare professional considering the patient’s individual medical history and treatment plan. The CDC also offers specific guidance for immunocompromised travelers, recognizing the increased risk of infection when traveling internationally.

What Comes Next: Ongoing Research and Surveillance

Further research is underway to better understand the optimal vaccination strategies for individuals with autoimmune rheumatic diseases, particularly those on immunosuppressants. Studies are exploring the impact of different timing strategies – vaccinating before starting immunosuppressive therapy, during a treatment pause, or continuing treatment as usual – on vaccine effectiveness.

Public health surveillance systems continue to monitor shingles incidence rates and vaccine effectiveness in various populations, including those with underlying medical conditions. This ongoing surveillance will help refine vaccination recommendations and ensure that individuals at risk receive the best possible protection against this painful and potentially serious illness. Healthcare providers are encouraged to report any adverse events following vaccination to the Vaccine Adverse Event Reporting System (VAERS) to contribute to ongoing safety monitoring.